arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Decoy Therapeutics Inc.

DCOY

$4.19 ▲ +0.08 (+1.95%) at close

13 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Decoy Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -169.2% ↗

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-12.52M

↓ -124.5% —

Operating Margin Operating profit as % of sales

-148.8%

↑ +37.6% —

FCF / Share Free cash flow per share

$-70.51

↑ +85.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Revenue Growth YoY (%)	—	—	—	N/M	-64.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-910%)	51.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+538%)	313.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3818%)	-34.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-528%)	26.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+226%)	—	—	—	—
EPS Growth YoY (%)	-48.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	81.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	74.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-92.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	38.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-124.5% Weak ↓ Weak Declining Year-over-year change in net income	55.5% Excellent ↑ Excellent Improving Year-over-year change in net income	60.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-147.6% Weak ↓ Weak Declining Year-over-year change in net income	-73.7% Weak ↓ Weak Declining Year-over-year change in net income	-6.0% Weak ↓ Weak Declining Year-over-year change in net income	68.4% Excellent ↑ Excellent Improving Year-over-year change in net income	36.3% Excellent ↑ Excellent Improving Year-over-year change in net income	12.8% Fair ↑ Fair Improving Year-over-year change in net income	-35.5% Weak Weak Year-over-year change in net income	-263.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	—	85.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	52.5% Excellent Excellent Year-over-year change in free cash flow	-34.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	30.0% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	60.1% Excellent Excellent Compound annual revenue growth over 3 years	50.8% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	—	—	—	12.7% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-148.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1092%)	-238.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1690%)	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	-140.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1271%)	-200.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1768%)	—	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	-197.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-334.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.39x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.40x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.67x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Return on Invested Capital (%)	-169.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-299.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-192.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-242.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-61.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-187.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-94.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-25.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-114.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-189.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-195.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-217.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-59.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-212.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-99.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-63.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-212.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1517%)	—	-237.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1681%)	—	-33.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-320%)	-33.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-321%)	-65.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-537%)	-236.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1674%)	-118.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-889%)	-66.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-544%)	-31.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	122.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+717%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Interest Coverage (x)	-2174.82x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-538.79x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-874.00x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-8728.15x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-898.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	-917.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-10.71M	$-2.43M	$-5.90M	$-12.11M	$-29.21M	$-11.12M	$-3.74M	$-9.83M	$-19.19M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Revenue per Share (USD)	—	—	—	$0.00	$133.39	$1.01K	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-129.10	$-86.81	$-460.87	$-1.78K	$-929.54	$-1.50K	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	—	$-70.51	$-471.96	$-993.35	$-739.38	—	—	—	—	—	—	—	—
Book Value per Share (USD)	—	$15.73	$161.02	$552.12	$2.57K	$2.79K	$7.03K	$1.54K	$4.90K	—	—	$-8.85K	—
Tangible Book Value per Share (USD)	—	$15.73	$161.02	$552.12	$1.98K	$1.67K	$1.14K	$1.54K	$4.90K	—	—	$-8.85K	—
Basic Weighted Avg Shares (shares)	96,967	64,179	27,219	17,713	13,796	5,195	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Working Capital (USD)	$5.82M	—	—	—	—	—	—	$9.21M	$28.69M	$58.58M	$89.40M	$33.16M	—
Total Equity (USD)	$5.89M	$1.51M	$5.29M	$10.38M	$38.72M	$22.16M	$10.58M	$9.28M	$29.11M	$59.32M	$92.19M	$-6.54M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Feb 26, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$0.00	$1.84M	$5.23M	$3.47M	$838.14K	$1.27M	$1.01M	$0.00	—	—
Depreciation Expense (USD)	$7.15K	$4.42K	$10.05K	$6.68K	$19.18K	$18.06K	$127.41K	$228.16K	$324.55K	$277.23K	$49.88K	$12.00K	—
Net Income, GAAP (USD)	$-12.52M	$-5.58M	$-12.54M	$-31.61M	$-12.77M	$-7.35M	$-6.94M	$-21.92M	$-34.43M	$-39.49M	$-29.14M	$-8.01M	—
Operating Cash Flow (USD)	$-4.83M	$-4.53M	$-12.85M	$-17.60M	$-10.20M	$-10.31M	$-11.58M	$-23.60M	$-27.72M	$-32.05M	$-20.75M	$-6.48M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters

Decoy Therapeutics Inc.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DCOY with peers